Emerging therapies for pulmonary hypertension: striving for efficacy and safety.
Kao
Peter N
PN
Faul
John L
JL
D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D011464:Epoprostenol / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D017079:Exercise Tolerance / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*
D014665:Vasodilator Agents; C048081:beraprost; D011464:Epoprostenol